L. Remontet, J. Esteve, A. Bouvier, P. Grosclaude, G. Launoy et al., Cancer incidence and mortality in France over the period 1978-2000, Rev Epiderniol Sante Publique, vol.5, issue.1, pp.3-30, 2003.
URL : https://hal.archives-ouvertes.fr/hal-00427472

F. Pages, A. Berger, M. Camus, F. Sanchez-cabo, A. Costes et al., Effector Memory T Cells, Early Metastasis, and Survival in Colorectal Cancer, New England Journal of Medicine, vol.353, issue.25, pp.2654-66, 2005.
DOI : 10.1056/NEJMoa051424

F. Sincrope, R. Rego, N. Foster, D. Sargent, and H. Windschitl, Microsattelite instability accounts for tumor site related differences in clinicopathologic variable and prognosis in human colon cancers, Am J, vol.101, issue.1 2, pp.28-46, 2006.

D. Cunningham and B. Glimelius, A phase III study of irinotecan (CPT-1 1) versus best supportive care in patients with metastatic colorectal cancer who have failed 5- fluorouracil therapy. V301 Study Group, Semin Oncol, vol.26, issue.1, pp.6-12, 1999.

D. Machover, E. Diaz-rubio, A. De-gramont, A. Schilf, J. Gastiaburu et al., Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines, Annals of Oncology, vol.7, issue.1, pp.95-103, 1996.
DOI : 10.1093/oxfordjournals.annonc.a010489

C. Tournigand, T. André, E. Achille, G. Lledo, and M. Flesh, FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study, Journal of Clinical Oncology, vol.22, issue.2, pp.229-237, 2004.
DOI : 10.1200/JCO.2004.05.113

L. Saltz, J. Cox, and C. Blanke, Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer, New England Journal of Medicine, vol.343, issue.13, pp.905-914, 2000.
DOI : 10.1056/NEJM200009283431302

J. Douillard, D. Cunningham, and A. Roth, Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial, The Lancet, vol.355, issue.9209, pp.1041-1047, 2000.
DOI : 10.1016/S0140-6736(00)02034-1

Y. Xu and M. Villalona-calero, Irinotecan mechanisms of tumor resistance and novels startegies for modulating its activity, Ann of Oncol, vol.13, pp.184-185, 2002.

A. Killian, D. Fiore, F. , L. Pessot, F. Blanchard et al., A Simple Method for the Routine Detection of Somatic Quantitative Genetic Alterations in Colorectal Cancer, Gastroenterology, vol.132, issue.2, pp.645-53, 2007.
DOI : 10.1053/j.gastro.2006.12.006

D. Salomon, R. Brandt, F. Ciardiello, and N. Normanno, Epidermal growth factor-related peptides and their receptors in human malignancies, Critical Reviews in Oncology/Hematology, vol.19, issue.3, pp.183-232, 1995.
DOI : 10.1016/1040-8428(94)00144-I

L. Saltz, M. Rubin, H. Hochster, and S. Tchekrneydian, IMC- C225) plus irinotecan (CPT-11) is active in CPT-1 1-refractory colorectal cancer that expresses epidermal growth factor receptor, 2001.

L. Saltz, N. Meropol, P. Loehrer, . Sr, M. Needle et al., Phase II Trial of Cetuximab in Patients With Refractory Colorectal Cancer That Expresses the Epidermal Growth Factor Receptor, Journal of Clinical Oncology, vol.22, issue.7, pp.1201-1209, 2004.
DOI : 10.1200/JCO.2004.10.182

M. Ducreux, M. Ychou, D. Khayat, J. Seitz, A. De-gramont et al., Essai de phase II randomisé, cétuximab en association avce l'irinotécan ou en monothérapie chez des patients ayant progressés sous irinotécan et exprimant le récepteur de 17Epidermal Growth Factor, 2004.

D. Cunningham, Y. Humblet, and S. Siena, Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer, New England Journal of Medicine, vol.351, issue.4, pp.337-345, 2004.
DOI : 10.1056/NEJMoa033025

A. Adenis and M. Hebbar, Targetting the epidermal growth factor receptor in colorectal cancer: clinical results, Bull Cancer, vol.92, pp.21-29, 2005.

C. Robert, J. Soria, and A. Spatz, Cutaneous side-effects of kinase inhibitors and blocking antibodies, The Lancet Oncology, vol.6, issue.7, pp.491-500, 2005.
DOI : 10.1016/S1470-2045(05)70243-6

M. Hebbar, A. Wacrenier, and C. Desauw, Lack of usefulness of epidermal growth factor receptor expression determination for cetuximab therapy in patients with colorectal cancer, Anti-Cancer Drugs, vol.17, issue.7, pp.855-857, 2006.
DOI : 10.1097/01.cad.0000217425.44584.9f

C. Messa, F. Russo, M. Caruso, D. Leo, and A. Egf, EGF, TGF-a, and EGF-R in Human Colorectal Adenocarcinoma, Acta Oncologica, vol.88, issue.3, pp.285-294, 1998.
DOI : 10.1038/bjc.1992.39

D. Salomon, R. Brandt, F. Ciardiello, and N. Normanno, Epidermal growth factor-related peptides and their receptors in human malignancies, Critical Reviews in Oncology/Hematology, vol.19, issue.3, pp.183-232, 1995.
DOI : 10.1016/1040-8428(94)00144-I

K. Chung, J. Shia, and N. Kemeny, Cetuximab Shows Activity in Colorectal Cancer Patients With Tumors That Do Not Express the Epidermal Growth Factor Receptor by Immunohistochemistry, Journal of Clinical Oncology, vol.23, issue.9, pp.1803-1821, 2005.
DOI : 10.1200/JCO.2005.08.037

M. Scartozzi, . Bearzi-1, and R. Berardi, Epidermal Growth Factor Receptor (EGFR) Status in Primary Colorectal Tumors Does Not Correlate With EGFR Expression in Related Metastatic Sites: Implications for Treatment With EGFR-Targeted Monoclonal Antibodies, Journal of Clinical Oncology, vol.22, issue.23
DOI : 10.1200/JCO.2004.00.117

M. Moroni, S. Veronese, and S. Benvenuti, Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study, The Lancet Oncology, vol.6, issue.5, pp.279-286, 2005.
DOI : 10.1016/S1470-2045(05)70102-9

D. Atkins, K. Reiffen, and C. Tegmeier, Immunohistochernical detection of EGFR in paraffin-embedded tumor tissues: variation in staining intensity due to choise of fixative and storage time of tissue sections, J Histochem, vol.52, pp.893-901, 2004.

A. Ooi, T. Takehana, and X. Li, Protein overexpression and gene amplification of HER-2 and EGFR in colorectal cancers: an immunohistochemical and fluorescent in situ hybridization study, Modern Pathology, vol.18, issue.8, pp.895-904, 2004.
DOI : 10.1200/JCO.2000.18.4.904

A. Lièvre, J. Bachet, L. Corre, and D. , Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer, Cancer Research, vol.66, issue.8, pp.3992-3995, 2006.
DOI : 10.1158/0008-5472.CAN-06-0191

D. Fiore, F. Blanchard, F. Charbonnier, and F. , Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy, British Journal of Cancer, vol.14, issue.8, pp.1-166, 2007.
DOI : 10.1093/jnci/92.3.205

D. Vallbohmer, W. Zhang, M. Gordon, and D. Yang, Molecular Determinants of Cetuximab Efficacy, Journal of Clinical Oncology, vol.23, issue.15, pp.3536-3544, 2005.
DOI : 10.1200/JCO.2005.09.100

P. Therasse, S. Arbuck, and . Eisenhauer, New Guidelines to Evaluate the Response to Treatment in Solid Tumors, JNCI: Journal of the National Cancer Institute, vol.92, issue.3, pp.205-216, 2000.
DOI : 10.1093/jnci/91.6.523

H. Lenz, E. Van-cutsem, S. Khambata-ford, and R. Mayer, Multicenter Phase II and Translational Study of Cetuximab in Metastatic Colorectal Carcinoma Refractory to Irinotecan, Oxaliplatin, and Fluoropyrimidines, Journal of Clinical Oncology, vol.24, issue.30, pp.4914-4921, 2006.
DOI : 10.1200/JCO.2006.06.7595

B. Vincenzi, D. Santini, C. Rabitti, R. Coppola, . Zobel et al., Cetuximab and irinotecan as third-line therapy in advanced colorectal cancer patients: a single centre phase II trial, British Journal of Cancer, vol.10, issue.6, pp.94-792, 2006.
DOI : 10.1634/theoncologist.10-4-250

T. Conroy, H. Bleiberg, and B. Glimelius, Quality of life in patients with advanced colorectal cancer, European Journal of Cancer, vol.39, issue.3, pp.287-94, 2003.
DOI : 10.1016/S0959-8049(02)00664-0

T. Conroy, A. Adenis, O. Bouche, Y. Merrouche, E. Mitry et al., Options et Recommandations; Institut national du cancer; Federation nationale des centres de lutte contre le cancer; Ligue nationale contre le cancer; Société nationale francaise de Castro-Enterologie; FFCD; GERCOR; Federation hospitalière de France; Federation nationale de Cancerologie des CHRU; Federation francaise de cancérologie des CHG. Recommendations for clinical practice: management with first-line palliative chemotherapy for patients with metastatic colorectalcancer Bull Cancer, Feb, vol.1, issue.932, pp.197-200, 2006.

P. Richter, W. Milanowski, A. Kubisz, and W. Nowak, Age as a prognosis factor in colorectal cancer treatment, Przegl Lek, vol.62, issue.12, pp.1440-1443, 2005.

B. Endreseth, P. Romundstad, H. Myrvold, U. Hestvik, T. Bjerkeset et al., Rectal Cancer in the Young Patient, Diseases of the Colon & Rectum, vol.49, issue.7, pp.993-1001, 2006.
DOI : 10.1007/s10350-006-0558-6

C. Kohne, D. Cunningham, and C. Di, Clinical determinants of survival in patients with 5-fluorouracil- based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients, Annals of Oncology, vol.13, issue.2, pp.308-311, 2002.
DOI : 10.1200/JCO.1999.17.5.1364

E. Mitry, J. Douillard, and E. Van-cutsem, Predictive factors of survival in patients with advanced colorectal cancer: an individual data analysis of 602 patients included in irinotecan phase III trials, Annals of Oncology, vol.15, issue.7, pp.1013-1017, 2004.
DOI : 10.1093/annonc/mdh267

C. Massacesi, A. Norman, and T. Price, A clinical nomogram for predicting long-term survival in advanced colorectal cancer, European Journal of Cancer, vol.36, issue.16, pp.2044-2052, 2000.
DOI : 10.1016/S0959-8049(00)00286-0

M. Meyers, . Vj-merluzzi, J. Ba-spengler, and . Biedler, Epidermal growth factor is increased in multidsug-resistan Chinese hamster and mouse tumor cells

M. Prewett, A. Hooper, and R. Bassi, Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-1 1) against human colorectal tumor xenografts, Clin Cancer Res, vol.8, pp.994-1003, 2002.

J. Nemunaitis, J. Cox, and W. Meyer, Irinotecan Hydrochloride (CPT-11) Resistance Identified by K-ras Mutation in Patients with Progressive Colon Cancer After Treatment with 5-Fluorouracil (5-FU), American Journal of Clinical Oncology, vol.20, issue.5, pp.527-529, 1997.
DOI : 10.1097/00000421-199710000-00020

A. Conlin, G. Smith, F. Carey, C. Wolf, and R. Steele, The prognostic significance of K-ras, p53, and APC mutations in colorectal carcinoma, Gut, vol.54, issue.9, pp.1283-1286, 2005.
DOI : 10.1136/gut.2005.066514

V. Bazan and M. Migliavacca, Specific codon 13 K-ras mutations are predictive of clinical outcome in colorectal cancer patients, whereas codon 12 K-ras mutations are associated with mucinous histotype, Annals of Oncology, vol.13, issue.9, pp.1438-1446, 2002.
DOI : 10.1093/annonc/mdf226

S. Anwar, I. Frayling, N. Scott, and G. Carlson, Systematic review of genetic influences on the prognosis of colorectal cancer, British Journal of Surgery, vol.91, issue.10, pp.1275-129, 2004.
DOI : 10.1002/bjs.4737

L. Assersohn, A. Norman, D. Cunningham, T. Benepal, P. Ross et al., Influence of metastatic site as an additional predictor for response and outcome in advanced colorectal carcinoma, British Journal of Cancer, vol.82, issue.11-12, pp.1800-1805, 1999.
DOI : 10.1002/(SICI)1097-0142(19980501)82:9<1626::AID-CNCR5>3.0.CO;2-8

D. Cunningham, S. Pyrhonen, R. James, C. Punt, T. Hickish et al., Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer, The Lancet, vol.352, issue.9138, pp.1413-1421, 1998.
DOI : 10.1016/S0140-6736(98)02309-5

U. Gessner, J. Bjorheim, S. Westring, S. Wahlberg, L. Pahlman et al., Ki-ras mutations and prognosis in colorectal cancer, Eur J Cancer, vol.34, issue.4, pp.5-18, 1998.